<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04459273</url>
  </required_header>
  <id_info>
    <org_study_id>20-000630</org_study_id>
    <secondary_id>NCI-2020-03766</secondary_id>
    <nct_id>NCT04459273</nct_id>
  </id_info>
  <brief_title>Prospective Exploratory Study of FAPi PET/CT With Histopathology Validation in Patients With Various Cancers</brief_title>
  <acronym>FAPI PET RDRC</acronym>
  <official_title>PET Biodistribution Study of 68Ga-FAPI-46 in Patients With Different Malignancies: An Exploratory Biodistribution Study With Histopathology Validation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jonsson Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jonsson Comprehensive Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This exploratory study investigates how an imaging technique called 68Ga-FAPi-46 PET/CT can&#xD;
      determine where and to which degree the FAPI tracer (68Ga-FAPi-46) accumulates in normal and&#xD;
      cancer tissues in patients with cancer. Because some cancers take up 68Ga-FAPi-46 it can be&#xD;
      seen with PET. FAP stands for Fibroblast Activation Protein. FAP is produced by cells that&#xD;
      surround tumors (cancer associated fibroblasts). The function of FAP is not well understood&#xD;
      but imaging studies have shown that FAP can be detected with FAPI PET/CT. Imaging FAP with&#xD;
      FAPI PET/CT may in the future provide additional information about various cancers.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVE:&#xD;
&#xD;
      I. To define the biodistribution of gallium Ga 68 fibroblast activation protein inhibitor&#xD;
      (FAPi)-46 (68Ga-FAPi-46) in normal and cancer tissues of patients with various malignancies.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. To evaluate the degree of 68Ga-FAPi-46 accumulation observed by positron emission&#xD;
      tomography (PET) imaging as opposed to the amount of FAP in excised cancer tissue.&#xD;
&#xD;
      II. To assess the correlation of 68Ga-FAPI-46 biodistribution with 18F-fluodeoxyglucose&#xD;
      (FDG), 68Ga-DOTATATE, or 18F-DOPA (FDOPA), depending on the specific indication.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      Patients receive 68Ga-FAPi-46 intravenously (IV) then 20-90 minutes later undergo&#xD;
      PET/computed tomography (CT).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 27, 2020</start_date>
  <completion_date type="Anticipated">July 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Biodistribution of gallium 68Ga-FAPi-46 in normal and cancer tissues</measure>
    <time_frame>At 20-90 minutes after injection]</time_frame>
    <description>Will be quantified by mean and maximum standardized uptake values (SUVmean and SUVmax).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>68Ga-FAPi-46 accumulation observed by positron emission tomography (PET)/computed tomography (CT)</measure>
    <time_frame>Up to year 2</time_frame>
    <description>Will be correlated with FAP expression in surgically removed or biopsy derived tumor tissue.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>To assess the 68Ga-FAPI-46 biodistribution correlation with other PET tracers</measure>
    <time_frame>60 minutes after tracer injection</time_frame>
    <description>The other PET tracer biodistribution will be described by mean and maximum standardized uptake values (SUVmean and SUVmax). The SUV of FAPI PET and the other PET tracers will be tested for correlation.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Bladder Carcinoma</condition>
  <condition>Cervical Carcinoma</condition>
  <condition>Cholangiocarcinoma</condition>
  <condition>Hematopoietic and Lymphoid Cell Neoplasm</condition>
  <condition>Hepatocellular Carcinoma</condition>
  <condition>Malignant Adrenal Gland Neoplasm</condition>
  <condition>Malignant Brain Neoplasm</condition>
  <condition>Malignant Pleural Neoplasm</condition>
  <condition>Malignant Skin Neoplasm</condition>
  <condition>Malignant Solid Neoplasm</condition>
  <condition>Malignant Testicular Neoplasm</condition>
  <condition>Malignant Thymus Neoplasm</condition>
  <condition>Neuroendocrine Neoplasm</condition>
  <condition>Thyroid Gland Carcinoma</condition>
  <condition>Urothelial Carcinoma</condition>
  <arm_group>
    <arm_group_label>Basic science (68GA-FAPI-46 PET/CT)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive 68Ga-FAPi-46 IV then 20-90 minutes later undergo PET/CT.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Computed Tomography</intervention_name>
    <description>Undergo PET/CT</description>
    <arm_group_label>Basic science (68GA-FAPI-46 PET/CT)</arm_group_label>
    <other_name>CAT</other_name>
    <other_name>CAT Scan</other_name>
    <other_name>Computerized Axial Tomography</other_name>
    <other_name>Computerized Tomography</other_name>
    <other_name>CT</other_name>
    <other_name>CT Scan</other_name>
    <other_name>tomography</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gallium Ga 68 FAPi-46</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Basic science (68GA-FAPI-46 PET/CT)</arm_group_label>
    <other_name>68Ga-FAPi-46</other_name>
    <other_name>Gallium-68-FAPi-46</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Positron Emission Tomography</intervention_name>
    <description>Undergo PET/CT</description>
    <arm_group_label>Basic science (68GA-FAPI-46 PET/CT)</arm_group_label>
    <other_name>Medical Imaging, Positron Emission Tomography</other_name>
    <other_name>PET</other_name>
    <other_name>PET Scan</other_name>
    <other_name>Positron Emission Tomography Scan</other_name>
    <other_name>Positron-Emission Tomography</other_name>
    <other_name>proton magnetic resonance spectroscopic imaging</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with the following cancer types:&#xD;
&#xD;
               -  Brain cancer&#xD;
&#xD;
               -  Bladder cancer&#xD;
&#xD;
               -  Urothelial cancer&#xD;
&#xD;
               -  Testicular cancer&#xD;
&#xD;
               -  Skin cancer&#xD;
&#xD;
               -  Thyroid cancer&#xD;
&#xD;
               -  Hepatocellular carcinoma&#xD;
&#xD;
               -  Cholangiocarcinoma&#xD;
&#xD;
               -  Thymus cancer&#xD;
&#xD;
               -  Pleural cancer&#xD;
&#xD;
               -  Cervical cancer&#xD;
&#xD;
               -  Adrenal cancer&#xD;
&#xD;
               -  Neuroendocrine tumors&#xD;
&#xD;
               -  Hematologic cancer&#xD;
&#xD;
          -  Patients who underwent a staging PET/CT scan within 3 months of enrollment (with any&#xD;
             PET tracer related to the indication including FDG, DOTATATE, FDOPA)&#xD;
&#xD;
          -  Patients who are scheduled to undergo surgical resection or tissue biopsy of the&#xD;
             primary tumor and/or metastasis&#xD;
&#xD;
          -  Patient can provide written informed consent&#xD;
&#xD;
          -  Patient is able to remain still for duration of imaging procedure (up to one hour)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient is pregnant or nursing&#xD;
&#xD;
          -  Patients with any new cancer therapy between the baseline PET/CT and the&#xD;
             investigational FAPI PET/CT&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeremie Calais</last_name>
    <role>Principal Investigator</role>
    <affiliation>UCLA / Jonsson Comprehensive Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Stephanie Lira</last_name>
    <phone>310-206-0596</phone>
    <email>StephanieLira@mednet.ucla.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kiara Booker</last_name>
    <phone>310-206-0596</phone>
    <email>KMBooker@mednet.ucla.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>UCLA / Jonsson Comprehensive Cancer Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stepanie Lira</last_name>
      <phone>310-206-0596</phone>
      <email>StephanieLira@mednet.ucla.edu</email>
    </contact>
    <contact_backup>
      <last_name>Kiara Booker</last_name>
      <phone>310-206-0596</phone>
      <email>KMBooker@mednet.ucla.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Jeremie Calais</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 1, 2020</study_first_submitted>
  <study_first_submitted_qc>July 1, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 7, 2020</study_first_posted>
  <last_update_submitted>July 12, 2021</last_update_submitted>
  <last_update_submitted_qc>July 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Cholangiocarcinoma</mesh_term>
    <mesh_term>Brain Neoplasms</mesh_term>
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
    <mesh_term>Neuroendocrine Tumors</mesh_term>
    <mesh_term>Thyroid Neoplasms</mesh_term>
    <mesh_term>Skin Neoplasms</mesh_term>
    <mesh_term>Testicular Neoplasms</mesh_term>
    <mesh_term>Pleural Neoplasms</mesh_term>
    <mesh_term>Adrenal Gland Neoplasms</mesh_term>
    <mesh_term>Thymus Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>FAPI-46</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

